Genomic Testing in the NCI-MATCH Cancer Trial

Tumor gene testing by a designated lab is the only pathway for patients to enroll in the NCI-MATCH precision medicine cancer trial.
To find patients who may be eligible, several commercial and academic laboratories are permitted by the National Cancer Institute to identify and refer potentially eligible patients to the trial. These referrals are based upon each lab’s standard tumor gene tests ordered by physicians at participating trial sites to guide clinical care for their patients.

NCI-MATCH Locations

The laboratory referral process applies to any cancer patient who gets tumor gene testing at a cancer center or community hospital that is participating in the trial. NCI-MATCH is open and enrolling patients at nearly 1100 clinical sites in every state, the District of Columbia, and Puerto Rico.

Genomic Testing and the Laboratory Referral Process

Following are the basic steps:

  1. The process begins after a physician at a participating trial site orders routine genomic sequencing from one of the designated commercial labs (listed below) to guide clinical care for his or her patient
  2. The designated lab looks for tumor gene abnormalities being studied in NCI-MATCH as part of its standard testing procedure
  3. If the patient matches to the trial, the lab contacts the patient’s physician and provides a written referral letter or email
  4. If the patient and the physician decide to pursue NCI-MATCH as a treatment option, the physician uses the laboratory referral letter or email to register the patient into the trial for a screening assessment (Step 0). Cancer patients who enroll in the NCI-MATCH trial for a screening assessment will do so knowing in advance that they have a tumor gene abnormality matching one of the treatment arms in the trial and that they have a type of cancer that is allowed in that arm.
  5. Centrally, trial leaders review the referral. If they verify the referral, they formally assign the patient to the treatment arm and notify their physician.
  6. During the screening assessment (Step 0), the physician will evaluate the patient further for the specific eligibility requirements for the treatment arm to which they match
  7. Once enrolled in the treatment arm, the patient will be treated with a drug or drug combination that targets the molecular changes in their tumor for as long as their tumor shrinks or remains stable

Disclaimer: Personnel in clinical sites must review the master protocol for complete eligibility requirements and NOT rely upon this overview, which is not intended to be a comprehensive listing of inclusion and exclusion criteria.

Designated Commercial Laboratories

Name Learn More Contact
Ashion Analytics, LLC

Joined 12/18/2019

Visit website Inquire via email
Caris Life Sciences® 

Joined 06/23/2017

Visit website Inquire via email
CellNetix Pathology and Laboratories

Joined 02/13/2019

Visit website Inquire via email
Foundation Medicine, Inc.

Joined 05/11/2017

Visit website Inquire via email
GenPath (BioReference Laboratories, Inc.)

Joined 08/03/2018

Visit website Inquire via email
NeoGenomics Laboratories, Inc.

Joined 07/02/2018

Visit website

Link to press release

Inquire via email
(This site has suspended outreach to patients.)
Joined 10/29/2018
Visit website Inquire via email
Quest Diagnostics Inc.

Joined 05/20/2019

Visit website

Link to press release

Inquire via email
Strata Oncology, Inc.

Joined 08/03/2018

Visit website

Link to press release

Inquire via email
Tempus Labs, Inc.

Joined 07/16/2018

Visit website 

Link to press release

Inquire via email
The Jackson Laboratory

Joined 01/10/2019

Visit website

Link to press release

Inquire via email

Designated Academic Laboratories

Name Joined
Augusta University – Georgia Esoteric & Molecular Diagnostic Laboratory 10/15/2018
Brigham and Women’s Hospital – Center for Advanced Molecular Diagnostics 04/17/2019
Cedars-Sinai Medical Center – Molecular Pathology Laboratory 02/13/2019
City of Hope National Medical Center – Clinical Molecular Diagnostics Laboratory 11/02/2018

Link to blog post

Columbia University – Laboratory of Personalized Genomic Medicine in the Department of Pathology and Cell Biology 07/25/2018

Link to news article

Johns Hopkins Genomics 01/29/2019
Massachusetts General Hospital – Center for Integrated Diagnostics 07/25/2018
MD Anderson Cancer Center 05/11/2017
Memorial Sloan Kettering Cancer Center 08/03/2017
Molecular Characterization Laboratory at the Frederick National Laboratory for Cancer Research 04/16/2019
National Cancer Institute – Laboratory of Pathology 07/03/2019
Stanford Health Care – Molecular Genetic Pathology Laboratory 02/25/2019
University of Chicago – Clinical Genomics Laboratory
(This site has suspended outreach to patients.)
University of Colorado – Colorado Molecular Correlates Laboratory 11/19/2018
University of Michigan – Michigan Medicine Molecular Diagnostics Laboratory 10/19/2018
University of Washington – Genetics and Solid Tumor Laboratory 09/16/2019
Weill Cornell Medicine – Clinical Genomics Laboratory 08/03/2018
Yale University – Yale Tumor Profiling Laboratory 06/20/2018


ECOG-ACRIN Cancer Research Group